


Chemical structure of a molecule, likely a selective SST5 agonist, shown in a 3D ball-and-stick model. The structure features a complex ring system with various substituents, including a carboxylic acid group and a methyl group.

Selective SST5 Agonists for the Treatment of Hyperinsulinism




Chemical structure of a molecule, likely a selective SST5 agonist, shown in a 3D ball-and-stick model. The structure features a complex ring system with various substituents, including a carboxylic acid group and a methyl group.

Congenital Hyperinsulinism Family Conference

Philadelphia, Pennsylvania

September 2019



3D rendering of a protein structure, likely a G-protein-coupled receptor (GPCR), shown in a yellowish-orange color. The structure is complex and folded, with a small blue and white molecular structure visible within a pocket of the protein.

Crinetics: Who We Are and What We Do




OUR VISION

To build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives




Our CHI hypothesis: an oral, selective-sst5 drug is the optimal strategy for treating all HI patients



sst5 Agonists: Positive results from preclinical studies


Rescue of hypoglycemia in rats induced by treatment with sulfonylurea glyburide




- Glyb + 10 mg/Kg CRN02481
- Glyb + 3 mg/Kg CRN02481
- Vehicle
- 30 mg/Kg glyburide

- Rescue insulin induced hypoglycemia
- Suppress insulin secretion
- Maintain glucagon levels

In an OGTT, CRNX agonist suppressed insulin...



...while maintaining glucagon levels



Our CHI Goals

- Deliver a new medicinal option for CHI clinicians and families
 - Oral pill (solution for infants)
 - *No Injections!*
 - Effective for most (*all?*) CHI mutations
 - Lower insulin levels
 - Prevent hypoglycemia
- Start human clinical trials asap!

sbetz@crinetics.com